Migraine drugmaker Alder Biopharmaceuticals to be acquired for nearly $2B by Lundbeck Danish drugmaker Lundbeck is set to buy Bothell, Wash.-based Alder Biopharmaceuticals in a deal that could be worth up to… Read More
Alder BioPharmaceuticals raises $170M in stock offering as FDA reviews its migraine therapy Alder BioPharmaceuticals has raised $170 million in a stock offering and is ramping up operations after filing an FDA application… Read More
